ZURICH (Reuters) — Roche Holding, the Swiss pharmaceutical giant, said Friday that its cancer drug, Avastin, did not help men with late-stage prostate cancer live longer in a clinical trial, marking another setback as the company tries to extend use of the blockbuster drug into new areas. Add to Portfolio Roche Holding AG Go to your Portfolio » The miss in prostrate cancer, announced on Friday, follows a similar disappointment last month with Avastin in gastric cancer but success in...
Full Story: The New York Times
